Skip to main content
Erschienen in: Clinical Research in Cardiology 7/2015

01.07.2015 | Original Paper

Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry

verfasst von: Jelena Kornej, Jedrzej Kosiuk, Gerhard Hindricks, Arash Arya, Philipp Sommer, Sascha Rolf, Daniela Husser, Gregory Y. H. Lip, Andreas Bollmann

Erschienen in: Clinical Research in Cardiology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Females with atrial fibrillation (AF) are at increased risk for ischemic stroke but have been under-represented in AF ablation cohorts. Whether the incidence of TE in women after catheter ablation is higher is unknown. We aimed to analyze the predictive value of thromboembolic scores and other clinical variants for thromboembolism (TE) after AF catheter ablation, separately in women and men.

Methods

TE was combined endpoint of early (within first month) and late (during long-term follow-up) stroke, transient ischemic attack, or systemic embolism. Oral anticoagulation was prescribed for 6 months after catheter ablation and discontinued if CHADS2 was <2 and no AF recurrences were documented.

Results

The study population (n = 2,069, 66 % male, 60 ± 10 years; 62 % paroxysmal AF) was followed for a median of 18 months (IQR 12–29). Overall 31 TE (1.5 %) occurred with 16 events within 30 days of ablation and 15 TE during the follow-up. Fourteen females (2.0 %) and 17 males (1.2 %) suffered TE (p = 0.128). On multivariate analysis, higher CHADS2 (HR 1.65, 95 % CI 1.10–2.47, p = 0.015), CHA2DS2-VASc (HR 1.42, 95 % CI 1.03–1.96, p = 0.034), R2CHADS2 (HR 1.76, 95 % CI 1.32–2.35, p < 0.001) scores, and eGFR <60 ml/min/1.73 m2 (HR 3.95, 95 % CI 1.23–12.7, p = 0.021) were significantly associated with TE in men. In females, LV-EF (HR 0.95, 95 % CI 0.91–0.99, p = 0.021) and CHA2DS2-VASc score (HR 1.52, 95 % CI 1.01–2.28, p = 0.044) remained significant predictors for TE.

Conclusion

TE rates after AF catheter ablation are low in both genders. In females, LV-EF and CHA2DS2-VASc score and in males all three scores and renal dysfunction were associated with TE.
Literatur
1.
Zurück zum Zitat Calkins H, Kuck KH, Cappato R et al (2012) HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14:528–606PubMedCrossRef Calkins H, Kuck KH, Cappato R et al (2012) HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14:528–606PubMedCrossRef
2.
Zurück zum Zitat Camm AJ, Al-Khatib SM, Calkins H et al (2012) A proposal for new clinical concepts in the management of atrial fibrillation. Am Heart J 164(292–302):e1PubMed Camm AJ, Al-Khatib SM, Calkins H et al (2012) A proposal for new clinical concepts in the management of atrial fibrillation. Am Heart J 164(292–302):e1PubMed
3.
Zurück zum Zitat Hunter RJ, McCready J, Diab I et al (2010) Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 98:48–53CrossRef Hunter RJ, McCready J, Diab I et al (2010) Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 98:48–53CrossRef
4.
Zurück zum Zitat Bunch TJ, Crandall BG, Weiss JP et al (2011) Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 22:839–845PubMedCrossRef Bunch TJ, Crandall BG, Weiss JP et al (2011) Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 22:839–845PubMedCrossRef
5.
Zurück zum Zitat Oral H, Chugh A, Ozaydin M et al (2006) Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 114:759–765PubMedCrossRef Oral H, Chugh A, Ozaydin M et al (2006) Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 114:759–765PubMedCrossRef
6.
Zurück zum Zitat Fang MC, Singer DE, Chang Y et al (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 112:1687–1691PubMedCentralPubMedCrossRef Fang MC, Singer DE, Chang Y et al (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 112:1687–1691PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30:1223–1229PubMedCrossRef Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30:1223–1229PubMedCrossRef
8.
Zurück zum Zitat Wang TJ, Massaro JM, Levy D et al (2003) A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290:1049–1056PubMedCrossRef Wang TJ, Massaro JM, Levy D et al (2003) A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290:1049–1056PubMedCrossRef
9.
Zurück zum Zitat Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRef Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRef
10.
Zurück zum Zitat Zhang XD, Tan HW, Gu J et al (2013) Efficacy and safety of catheter ablation for long-standing persistent atrial fibrillation in women. Pacing Clin Electrophysiol 36:1236–1244PubMedCrossRef Zhang XD, Tan HW, Gu J et al (2013) Efficacy and safety of catheter ablation for long-standing persistent atrial fibrillation in women. Pacing Clin Electrophysiol 36:1236–1244PubMedCrossRef
11.
Zurück zum Zitat Kornej J, Hindricks G, Kosiuk J et al (2013) Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 6:868–874PubMedCrossRef Kornej J, Hindricks G, Kosiuk J et al (2013) Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 6:868–874PubMedCrossRef
12.
Zurück zum Zitat Kosiuk J, Kornej J, Bollmann A et al (2014) Early cerebral thromboembolic complications following radiofrequency catheter ablation of atrial fibrillation: incidence, characteristics and risk factors. Heart Rhythm 11:1934–1940PubMedCrossRef Kosiuk J, Kornej J, Bollmann A et al (2014) Early cerebral thromboembolic complications following radiofrequency catheter ablation of atrial fibrillation: incidence, characteristics and risk factors. Heart Rhythm 11:1934–1940PubMedCrossRef
13.
Zurück zum Zitat Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:1360–1420PubMedCrossRef Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:1360–1420PubMedCrossRef
14.
Zurück zum Zitat Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef
15.
Zurück zum Zitat Piccini JP, Stevens SR, Chang Y et al (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (anticoagulation and risk factors in atrial fibrillation) study cohorts. Circulation 127:224–232PubMedCrossRef Piccini JP, Stevens SR, Chang Y et al (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (anticoagulation and risk factors in atrial fibrillation) study cohorts. Circulation 127:224–232PubMedCrossRef
16.
Zurück zum Zitat Eitel C, Hindricks G, Sommer P et al (2009) Circumferential pulmonary vein isolation and linear left atrial ablation as a single-catheter technique to achieve bidirectional conduction block: the pace-and-ablate approach. Heart Rhythm 7:157–164PubMedCrossRef Eitel C, Hindricks G, Sommer P et al (2009) Circumferential pulmonary vein isolation and linear left atrial ablation as a single-catheter technique to achieve bidirectional conduction block: the pace-and-ablate approach. Heart Rhythm 7:157–164PubMedCrossRef
17.
Zurück zum Zitat Calkins H, Brugada J, Packer DL et al (2007) HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 9:335–379PubMedCrossRef Calkins H, Brugada J, Packer DL et al (2007) HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 9:335–379PubMedCrossRef
18.
Zurück zum Zitat Go AS, Fang MC, Udaltsova N et al (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363–1369PubMedCentralPubMedCrossRef Go AS, Fang MC, Udaltsova N et al (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363–1369PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Roldan V, Marin F, Manzano-Fernandez S et al (2013) Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109:956–960PubMedCrossRef Roldan V, Marin F, Manzano-Fernandez S et al (2013) Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109:956–960PubMedCrossRef
20.
Zurück zum Zitat Meyer S, Brouwers F, Voors A, et al (2014) Sex differences in new-onset heart failure. Clin Res Cardiol (epub ahead of print) Meyer S, Brouwers F, Voors A, et al (2014) Sex differences in new-onset heart failure. Clin Res Cardiol (epub ahead of print)
21.
Zurück zum Zitat Witt BJ, Gami AS, Ballman KV et al (2007) The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 13:489–496PubMedCrossRef Witt BJ, Gami AS, Ballman KV et al (2007) The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 13:489–496PubMedCrossRef
22.
Zurück zum Zitat Jang SJ, Kim MS, Park HJ et al (2013) Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart 99:17–21PubMedCrossRef Jang SJ, Kim MS, Park HJ et al (2013) Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart 99:17–21PubMedCrossRef
23.
Zurück zum Zitat Rietbrock S, Heeley E, Plumb JM, Van Staa TP (2008) Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 156:57–64PubMedCrossRef Rietbrock S, Heeley E, Plumb JM, Van Staa TP (2008) Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 156:57–64PubMedCrossRef
24.
Zurück zum Zitat Vaccarino V, Badimon L, Corti R et al (2011) Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. Cardiovasc Res 90:9–17PubMedCentralPubMedCrossRef Vaccarino V, Badimon L, Corti R et al (2011) Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. Cardiovasc Res 90:9–17PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249PubMedCrossRef Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249PubMedCrossRef
26.
Zurück zum Zitat Lowe GD (2002) Hormone replacement therapy: prothrombotic vs. protective effects. Pathophysiol Haemost Thromb 32:329–332PubMedCrossRef Lowe GD (2002) Hormone replacement therapy: prothrombotic vs. protective effects. Pathophysiol Haemost Thromb 32:329–332PubMedCrossRef
27.
Zurück zum Zitat Novella S, Heras M, Hermenegildo C, Dantas AP (2012) Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 32:2035–2042PubMedCrossRef Novella S, Heras M, Hermenegildo C, Dantas AP (2012) Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 32:2035–2042PubMedCrossRef
28.
Zurück zum Zitat Fradley MG, Larson MG, Cheng S et al (2011) Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 108:1341–1345PubMedCentralPubMedCrossRef Fradley MG, Larson MG, Cheng S et al (2011) Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 108:1341–1345PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Hijazi Z, Oldgren J, Andersson U et al (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125:1605–1616PubMedCrossRef Hijazi Z, Oldgren J, Andersson U et al (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125:1605–1616PubMedCrossRef
Metadaten
Titel
Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry
verfasst von
Jelena Kornej
Jedrzej Kosiuk
Gerhard Hindricks
Arash Arya
Philipp Sommer
Sascha Rolf
Daniela Husser
Gregory Y. H. Lip
Andreas Bollmann
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 7/2015
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-015-0823-6

Weitere Artikel der Ausgabe 7/2015

Clinical Research in Cardiology 7/2015 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.